Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Apr 30, 2024
- Pharmaceuticals
- R&D
CHMP Recommends EU Approval of Alecensa as an Adjuvant Treatment for Resected ALK-Positive Early-Stage Lung Cancer
TOKYO, April 30, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued an Investor Update regarding anti-cancer agent/ALK inhibitor Alecensa® (alectinib). The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended to approve Alecensa monotherapy as adjuvant treatment following complete tumor resection for adult patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer at high risk of recurrence*.
*Stage IB (tumours ≥ 4 cm) - IIIA non-small cell lung cancer (UICC/AJCC 7th edition)
Please refer to the link below for details of the Investor Update:
CHMP recommends EU approval of Roche’s Alecensa as the first adjuvant treatment for resected ALK-positive early-stage lung cancer
https://www.roche.com/investors/updates/inv-update-2024-04-26
